Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of “Hold” by Analysts

Pulmonx Corporation (NASDAQ:LUNG) has received a consensus rating of “Hold” from the seven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.5833.

LUNG has been the subject of several recent research reports. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Monday, July 13th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of LUNG. R Squared Ltd bought a new stake in Pulmonx during the first quarter valued at about $26,000. Cerity Partners LLC bought a new position in shares of Pulmonx in the fourth quarter worth about $27,000. FNY Investment Advisers LLC bought a new position in shares of Pulmonx in the third quarter worth about $29,000. Opal Capital LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $29,000. Finally, Regatta Capital Group LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $30,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Price Performance

NASDAQ LUNG opened at $1.21 on Thursday. The company has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.50. Pulmonx has a 52 week low of $1.13 and a 52 week high of $3.88. The company has a quick ratio of 4.04, a current ratio of 4.91 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $51.11 million, a P/E ratio of -0.93 and a beta of 0.30.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. The company had revenue of $20.59 million during the quarter, compared to analyst estimates of $20.43 million. Equities research analysts anticipate that Pulmonx will post -1.13 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.